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Abstract Bacterial infections are the most common cause for
treatment-related mortality in patients with neutropenia after
chemotherapy. Here, we discuss the use of antibacterial pro-
phylaxis against bacteria and Pneumocystis pneumonia (PCP)
in neutropenic cancer patients and offer guidance towards the
choice of drug. A literature search was performed to screen all
articles published between September 2000 and January 2012
on antibiotic prophylaxis in neutropenic cancer patients. The
authors assembled original reports and meta-analysis from the
literature and drew conclusions, which were discussed and
approved in a consensus conference of the Infectious Disease
Working Party of the German Society of Hematology and
Oncology (AGIHO). Antibacterial prophylaxis has led to a
reduction of febrile events and infections. A significant reduc-
tion of overall mortality could only be shown in a meta-
analysis. Fluoroquinolones are preferred for antibacterial and
trimethoprim–sulfamethoxazole for PCP prophylaxis. Due to
serious concerns about an increase of resistant pathogens, only
patients at high risk of severe infections should be considered
for antibiotic prophylaxis. Risk factors of individual patients
and local resistance patterns must be taken into account. Risk
factors, choice of drug for antibacterial and PCP prophylaxis
and concerns regarding the use of prophylactic antibiotics are
discussed in the review.
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Introduction
Patients with hematological and oncological diseases are at
increased risk for bacterial infections and pneumonia caused
by Pneumocystis jirovecii (PCP) because of their disease-
related and therapy-induced immunosuppression. As infections
are the leading cause for non-relapse mortality, broad-spectrum
antibiotic therapy is introduced as soon as an infectious prob-
lem is suspected. Despite early empirical antibiotic therapy, the
infection-related mortality in neutropenic cancer patients is 4–
7 % [1, 2]. The administration of systemic antibacterial pro-
phylaxis may aim at a reduction of severe infections, a delay of
the onset of such infections to a later phase of neutropenia,
avoidance of infection-related treatment delays, reduction of
hospitalization, reduction of treatment costs or a combination of
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these goals. To reduce the risk of infectious complications
during the period of chemotherapy-induced neutropenia, various
prophylactic approaches including the systemic use of antibiot-
ics were introduced and widely studied. The decision for or
against the administration of a prophylactic antibiotic regime is
guided by the risk of an individual patient to acquire a severe,
life-threatening infection, carefully balanced against the poten-
tial risks of long-term administration of a broad-spectrum anti-
bacterial agent with systemic activity. Several studies have
shown that antibacterial prophylaxis led to a reduction of febrile
events and documented infections, their tolerability is generally
good and hospitalization may be avoided or shortened, result-
ing in cost saving. On the other hand, the concept of antibiotic
prophylaxis is challenged because of possible side effects such
as development of resistance and toxicity of the drugs.
For this review, papers on antibacterial and PCP prophylaxis
published in scientific journals from September 2000 to January
2012 were searched and evaluated according to the 2001
evidence-based medicine criteria used by the Infectious
Diseases Society of America (IDSA) (Table 1) [3]. The authors
assembled in January 2012 to develop practice recommendations
based on the recent literature. These recommendations were
then extensively discussed at the Infectious Diseases Working
Party of the German Society of Hematology and Oncology
(AGIHO) plenary meeting, resulting in an agreement regard-
ing each recommendation. This manuscript summarizes the
recommendations on antibacterial and PCP prophylaxis for
neutropenic cancer patients resulting from this process.
Guidelines for antiviral and antifungal prophylaxis can be
found in other publications of the AGIHO [4, 5]. Furthermore,
prophylaxis of patients with allogeneic stem cell transplantation
is addressed in a separate guideline of the AGIHO [6].
Definitions
Neutropenia
Neutropenia is defined as a neutrophil count below 500/μl
or <1,000/μl with predicted decline to less than 500/μl
within the next 2 days, or leukopenia <1,000/μl when there
is no differential leukocyte count available.
IDSA grading system for ranking recommendations
Regarding the IDSA grading system for ranking recommen-
dations, see Table 1.
Patients and risk factors
The risk of developing an infection following chemotherapy
depends on the severity and duration of neutropenia [7, 8]. In a
guideline published a decade ago, the AGIHO defined three
risk groups depending on the duration of neutropenia —
patients with an expected duration of neutropenia of less than
5 days generally are at low risk, whereas patients with an
expected duration of neutropenia of more than 10 days are at
high risk, with a risk of acquiring an infection exceeding 90%
[9]. Patients with an expected duration of neutropenia between
6 and 10 days were classified as intermediate risk group. Other
guidelines divide the patients into two risk groups with neu-
tropenia of more or less than 7 days based on two recently
published clinical trials [1, 10–12]. Importantly, none of these
classifications are based on prospective studies. However,
judging the risk of an individual patient on his expected
duration of neutropenia has become clinical practice in many
centers. We will also assume two risk groups for easier appli-
cability, the low-risk group being patients with an expected
duration of neutropenia of less than 7 days and the high-risk
group those patients with duration of neutropenia of 7 days or
more or with additional risk factors.
Additional factors which may increase the risk of infection
are the type and stage of the underlying malignancy, the remis-
sion status, disruption of physiological skin or mucosal barriers
as well as age and comorbidities of an individual patient.
Furthermore, the number and type of pretreatments or the use
of other immunosuppressive agents such as high-dose
Table 1 Infectious Diseases Society of America–United States Public
Health Service Grading System for ranking recommendations [3]
Category, grade Definition
Strength of recommendation
A Good evidence to support a
recommendation for use
B Moderate evidence to support
a recommendation for use
C Poor evidence to support a
recommendation
D Moderate evidence to support
a recommendation against use
E Good evidence to support a
recommendation against use
Quality of evidence
I Evidence from ≥1 properly
randomized, controlled trial
II Evidence from ≥1 well-designed
clinical trial, without randomization;
from cohort or case-controlled
analytic studies (preferably from >1
center); from multiple time-series;
or from dramatic results from
uncontrolled experiments
III Evidence from opinions of respected
authorities, based on clinical
experience, descriptive studies,
or reports of expert committees
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glucocorticosteroids or lymphocyte-depleting substances may
have an impact on the risk of infection. Patients receiving their
first cycle of chemotherapy are at a higher risk of infection than
in following cycles. However, if a febrile episode occurred
during the first cycle, the risk of infection is increased in
subsequent cycles of chemotherapy. Moreover, the “social en-
vironment,” including the availability of a direct caregiver,
telephone, option of quick transportation from home to hospital,
residence within a defined maximum distance from the hospital
and appropriate verbal communication and intellectual under-
standing of an individual patient should be considered for the
decision of anti-infective prophylaxis [8, 13–16] (Table 2).
In patients with autologous stem cell transplantation, the
risk of infection depends primarily on the length of neutro-
penia which is usually longer than 7 days. More detailed
information can be found in the relevant guideline [17].
The use of the anti-CD20 antibody rituximab or anti-
CD52 antibody alemtuzumab leads to an increased inci-
dence of fungal, viral or protozoal infections [18–21], while
a substantially increased risk of bacterial infections has not
been reported [22–26].
Clinical presentation and spectrum of pathogens
in neutropenic infections
In most cases of infection in a neutropenic patient, fever is the
first sign [27]. Typical clinical symptoms such as local signs of
infection as part of an inflammatory response may be missing.
In approximately half of the patients, a focus of infection
cannot be detected at the onset of fever; therefore, it is classi-
fied as fever of unknown origin (FUO). In up to a third of
patients, bacteremia can be diagnosed [1, 28], with coagulase-
negative staphylococci, α-hemolytic streptococci and
Staphylococcus aureus being predominant among gram-
positive pathogens. With regard to gram-negative pathogens,
enterobacteria such as Escherichia coli and Klebsiella spp. as
well as non-fermenters such as Pseudomonas aeruginosa
predominate [29–31]. A gram-negative sepsis is still associat-
ed with substantial mortality [32]. For this reason, antibiotic
prophylaxis using agents active against gram-negative bacte-
ria, particularly fluoroquinolones, was introduced in many
hospitals, resulting in an overall decrease of bacteremias, but
also in an increased proportion of infections caused by gram-
positive bacteria [33]. At present, the proportion of gram-
positive pathogens in neutropenic patients with micro-
biologically documented infections is typically around 60–
70% [29, 31, 34, 35]; however, as this may differ substantially
between cancer centers [36], the local epidemiology should
always be considered before deciding on an antibacterial
prophylaxis regimen.
Efficacy of prophylaxis
The efficacy of systemic antibacterial prophylaxis was investi-
gated in a multitude of clinical trials and several meta-analyses.
The results of the two most important large double-blind,
placebo-controlled studies are described briefly: Bucaneve et
al. examined the use of levofloxacin in 675 patients with
hematological malignancies or solid tumors and an expected
length of neutropenia (neutrophil count less than 1,000/μl) of
more than 7 days. A significant reduction of febrile episodes
and microbiologically documented infections, especially gram-
negative bacteremias, could be shown in the levofloxacin arm.
Mortality was lower in the levofloxacin group, but the study
was not powered to show this with statistical significance [1]. In
the study by Cullen et al. [12], 1,565 patients with solid tumors
or lymphomas receiving outpatient chemotherapy were given
levofloxacin or placebo for an expected period of neutropenia
of less than 7 days. The incidence of febrile episodes, probable
infections and hospitalization for infection could be reduced
significantly. Also, there were fewer severe infections and a
lower overall mortality in the prophylaxis group, but this dif-
ference was not statistically significant [12].
These observations were confirmed in a large meta-
analysis comprising a total of 13,579 patients from 109 studies
conducted between 1973 and 2010 [37]. Most of the studies
included high-risk patients with hematological diseases such
as acute leukemias and compared different prophylactic strat-
egies with placebo or no intervention. Due to the larger
number of patients included in the meta-analysis compared
to the single trials, a significant reduction of infection-related
death with a risk ratio (RR) of 0.61 (95 % confidence interval
[CI], 0.48–0.77) and a reduction in all-cause mortality (RR
0.66; 95 % CI, 0.55–0.79) were calculated for patients receiv-
ing antibacterial prophylaxis as compared to placebo or no
intervention. A decrease in all-cause mortality could also be
shown in the subgroup of 3,776 patients included from studies
testing fluoroquinolone prophylaxis versus no prophylaxis
Table 2 Patient-related risk factors
Duration of neutropenia 500/µl
Type and stage of underlying malignancy
Number of cycles and type of cytotoxic/immunosuppressive
pretreatment
Concomitant immunosuppressive therapy
First cycle of chemotherapy
Previous episode of febrile neutropenia
Disruption of physiological skin or mucosal barriers
Chronic wounds
Age
Comorbitities (e.g., diabetes mellitus, iron overload,
chronic lung disease)
Social conditions
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(RR 0.54; 95 % CI, 0.40–0.74). Microbiologically docu-
mented gram-negative as well as gram-positive infections
including bacteremias were significantly reduced in patients
receiving antibacterial prophylaxis. An increase of 3.6 % in
adverse events due to prophylaxis as compared to no prophy-
laxis is reported with 2.1 % more events (3.9 % versus 1.8 %)
leading to treatment discontinuation [37].
A meta-analysis including only randomized, blinded,
placebo-controlled trials from 1987 to 2005 with a total of
2,721 patients could not demonstrate a significant, but only a
trend towards, reduction of overall mortality [38], while effi-
cacy data were consistent with the study from Bucaneve et al.
and with the 2012 meta-analysis [1, 37]. It has to be kept in
mind that this meta-analysis was strongly influenced by the
non-infectious mortality among low-risk patients in the Cullen
et al. study, which might obscure a potential survival benefit
with regard to the infection-related mortality (Table 3).
Antibacterial prophylaxis, particularly with fluoroquino-
lones, can prevent febrile episodes, clinically or microbio-
logically documented bacterial infections including
bacteremias and hospitalization of outpatients. A reduction
in infection-related as well as all-cause mortality could be
shown in a large meta-analysis [37]. In order to derive
recommendations from the data described above, the risk
reduction has to be weighed against adverse effects, espe-
cially the development of resistance to widely used antibac-
terial agents among clinically relevant pathogens. A
reduction of overall mortality can be assumed in high-risk
populations with a number needed to treat (NNT) below 50
(43 according to the study of Bucaneve et al., 34 according
to the meta-analysis of Gafter-Gvili et al.) and avoidance of
neutropenic fever with a NNT of around 5 [1, 37, 39]. As
with other interventions, NNT decreases with increasing
underlying risk. Therefore, prophylaxis is recommended in
high-risk patients. Concerning avoidance of fever and infec-
tions, this is a strong recommendation; concerning mortality
reduction, the recommendation is weaker (Table 4). In low-
risk patients, a reduction of neutropenic fever and avoidance
of hospitalization can be achieved. This effect is most pro-
nounced during the first cycle of chemotherapy. On the
other hand, a reduction of mortality was not unequivocally
shown for low-risk patients. One meta-analysis showed a
mortality reduction with a NNT of 72 [39], but it included
older studies with an unacceptably high baseline event rate
to be attributed to low-risk patients. Assuming that in low-
risk patients a similar relative risk reduction as in high-risk
patients can be achieved, the NNT to prevent one infection-
related death would be around 250 at a baseline risk of 1 %
and a relative risk of 0.6 (i.e., otherwise healthy individuals
with low-intensity chemotherapy). In addition, the prophy-
lactic administration of a fluoroquinolone in low-risk
patients would prohibit the use of a fluoroquinolone for
treatment of infection in the outpatient setting. Therefore,
antibacterial prophylaxis can generally not be recommended
in low-risk patients. In specific situations such as the first
chemotherapy cycle [15], aggressive cytostatic regimens
with high baseline infection rate or in elderly patients;
however, it may be considered because it reduces the inci-
dence of infections and febrile episodes.
Substances for antibacterial prophylaxis
Studies conducted in the 1970s used non-absorbable antibiotics
such as colistin, polymyxin B or neomycin for selective bowel
decontamination. Due to the lack of systemic activity, gastro-
intestinal tolerability problems and the risk of selection of
resistant bacteria, most institutions have switched to











Gafter-Gvili et al. [37] (meta-analysis, drug vs. none) 5635 8.8 % 0.66** 5.6 % 0.61** 60.7 % 0.80 **
Gafter-Gvili et al. [37] (meta-analysis, quinolone vs. none) 3776 5.3 % 0.54** 2.9 % 0.51 ** 53.8 % 0.74 **
Bucaneve et al. [1] (low and high risk, levofloxacin vs. placebo) 760 5.0 % 0.54 ns 3.9 % 0.63 ns 84.8 % 0.76 **
Cullen et al. [12] (low risk, levofloxacin vs. placebo) 1565 0.5 % 1.00 0.71 **
- Cumulative 4.6%a 0.86 15.2 % 0.44 **
- First cycle 2.3 % 0.67 7.9 %
Imran et al. [38] (meta-analysis, quinolone vs. placebo) 2721 5.3 % 0.76 ns 39.7 %2 0.76 nsb
N number of patients, RR relative risk, ns not significant
a Overall mortality reported as personal communication in reference [38] and as 30-day mortality in reference [39]
b Heterogeneous data. Only first cycle from Cullen et al. [12] is used for this analysis
**Significant
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trimethoprim–sulfamethoxazole (TMP/SMX) or fluoroquino-
lones. These substances have a broad spectrum of activity and
are well absorbed from the gastrointestinal tract. TMP/SMX is
not active against P. aeruginosa, and resistance to this drug
combination among gram-negative target pathogens such as E.
coli or Klebsiella spp. has been observed already in the 1990s.
However, significant differences in clinical efficacy have not
been shown in direct comparisons [40–42]. Both types of drugs
show similar risk reductions of the outcome parameters men-
tioned above in comparison to placebo [37].
TMP/SMX is less well tolerated as compared with fluo-
roquinolones (relative risk for side effects requiring discon-
tinuation about 2 compared to quinolones by both direct and
indirect comparison [37]), and it may be associated with
bone marrow toxicity in patients given this drug combina-
tion daily for more than 2–3 weeks.
Therefore, if a high local resistance rate and an individual
intolerance to fluoroquinolones are excluded, a fluoroqui-
nolone should be preferred in patients in whom systemic
antibacterial prophyaxis is indicated (A-II, Table 4).
The fluoroquinolones available for clinical use differ in their
spectrum of activity. Ciprofloxacin and levofloxacin weremost
frequently tested in clinical trials. Compared to ciprofloxacin,
levofloxacin is less effective against P. aeruginosa, but has the
advantage of activity against gram-positive bacteria such as
Streptococcus spp. In 2012, a warning regarding the off-label
use of levofloxacin was issued because of rare but severe side
effects including life-threatening hepatotoxicity. In Germany,
levofloxacin is not approved for the prophylactic use in the
setting of chemotherapy-induced neutropenia, whereas cipro-
floxacin is. Considering this fact and in the light of the recent
box warning, the authors recommend to prefer ciprofloxacin
for antibacterial prophylaxis in neutropenic cancer patients.
While moxifloxacin has a broad activity against aero-
bic and anaerobic gram-positive and gram-negative
pathogens, it has no efficacy against P. aeruginosa
and appears to be associated with a higher risk of
Clostridium difficile-associated enterocolitis than levo-
floxacin [43]. As yet, no properly designed clinical study
showing a benefit of moxifloxacin for antibacterial pro-
phylaxis in neutropenic cancer patients has been reported.
A recently published trial has demonstrated a reduction
of bacteremias by moxifloxacin in a small number of
patients undergoing autologous hematopoietic stem cell
transplantation [44].
Combination of a fluoroquinolone with an agent
active against gram-positive bacteria
In order to prevent gram-positive infections, combinations of
fluoroquinolones with antibiotics active against gram-positive
pathogens such as oral penicillin, vancomycin or a macrolide
have been studied in neutropenic patients. A randomized
placebo-controlled study investigated the use of ciprofloxacin
in combination with roxithromycin versus no antibiotic pro-
phylaxis in patients with small cell lung cancer during the first
cycle of chemotherapy. In the prophylaxis group, the incidence
of febrile leukopenia, documented gram-positive and gram-
negative infections and infection-associated deaths were sig-
nificantly reduced [45]. A comparison with single-agent cipro-
floxacin was not included in this study. Several small trials
compared combination prophylaxis with fluoroquinolone pro-
phylaxis alone. Two meta-analyses including more than 1,200
patients found a significant reduction in gram-positive infec-
tions and septicemia with the addition of an antibiotic active
against gram-positive pathogens, however, a significant reduc-
tion of clinically documented infections, febrile neutropenia or
mortality could not be demonstrated [37, 46]. On the other
hand, significantly more side effects were reported in patients
Table 4 Recommendations for
antibacterial prophylaxis




Antibiotic prophylaxis is indicated for
Low risk, regarding fever and infection B-I
Low risk, regarding mortalitya C-II
High risk, regarding fever and infection A-I
High risk, regarding mortality B-II
Fluoroquinolone prophylaxis should be preferred to TMP/SMX A-II
Drug of choice: ciprofloxacin (500mg twice daily) or levofloxacin (500mg once daily)
(not approved for this indication in Germany)
A-II
Addition of a gram-positive active agent to quinolone prophylaxis (discouraged) E-II
Start of prophylaxis with onset of neutropenia in low-risk patients B-III
Start of prophylaxis with start of cytostatic drugs in high-risk patients B-III
Termination of prophylaxis with the start of empirical antibiotics or end of neutropenia B-III
Use of FQ for empirical therapy if used for prophylaxis (discouraged) E-III
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on combination therapy. In particular, the administration of
rifampin resulted in a significantly increased rate of side effects
such as gastrointestinal intolerance or abnormal liver function
tests.
In summary, the addition of prophylactic antibiotics with
specific activity against gram-positive pathogens to a fluo-
roquinolone is not recommended (E-II, Table 4).
Beginning and duration of prophylaxis
There are no comparative studies addressing the question
when to start prophylactic antibiotics and how long to admin-
ister them. In those patients with expected short duration of
neutropenia (solid tumors, lymphomas), in whom antibacteri-
al prophylaxis is considered at all, prophylaxis is usually
started after the end of chemotherapy and given throughout
the period of neutropenia [12, 45]. In high-risk patients, how-
ever, antibiotic prophylaxis in clinical trials was administered
almost exclusively from the start of chemotherapy until the
end of neutropenia or until the onset of systemic antimicrobial
therapy [1, 47]. In patients receiving induction chemotherapy
for acute leukemia, prophylaxis should begin with the first day
of chemotherapy because of the functional neutropenia in-
duced by the disease itself. With the end of neutropenia or
onset of systemic antimicrobial treatment, antibiotic prophy-
laxis should be stopped (B-III). The use of quinolones for
empirical treatment is not recommended if prior prophylaxis
has been carried out with a fluoroquinolone (A-III, Table 4).
If a cytostatic treatment in acute leukemia patients is
given without antibacterial prophylaxis, an intensive clinical
monitoring is required to ensure an immediate start of anti-
biotic therapy in case of a suspected infection.
Concerns on resistance development
One of the main concerns regarding antibiotic prophylaxis in
any patient population is the development or selection of
multidrug-resistant pathogens. This has led some experts to
withhold a recommendation for antibiotic prophylaxis in neu-
tropenic cancer patients [11]. Regarding the risk of the emer-
gence of resistance, several issues need to be considered:
1. Does antibacterial prophylaxis in cancer patients really
lead to an excess increase in the proportion of multidrug-
resistant pathogens?
2. Are infections due to fluoroquinolone-resistant patho-
gens more threatening than infections from sensitive
strains of the same pathogen?
3. If there is an increase in multidrug-resistant pathogens,
does it lead to an increased infection rate due to these
pathogens and does this result in increased mortality?
4. As a consequence, should a recommendation for anti-
bacterial prophylaxis in neutropenic cancer patients be
restricted to centers with a low (e.g., <20 %) prevalence
of resistance against the prophylactic antibacterials (typ-
ically fluoroquinolones) among target pathogens such
as E. coli or Klebsiella spp. since in areas with a high
prevalence of resistance no benefit from this prophylax-
is can be expected?
5. Is it ethically justified to withhold a potentially benefi-
cial antibacterial prophylaxis from cancer patients at
risk for serious neutropenic infections today, in order
to avoid an increasing risk of infections due to resistant
pathogens in future patients?
While none of these questions can be answered definitely,
there are some arguments to consider for most of them. Data
regarding the additional effect of drug resistance on morbidity
and mortality in hospital acquired infections are conflicting
[48–50], whereas there is little doubt that hospital acquired
infections by themselves pose a major problem and should
generally be avoided if possible. This consideration rather
favors the use of prophylactic antibiotics, since it has been
shown that they reduce the likelihood of infections in neutro-
penic cancer patients. From a broader perspective, neutropenic
cancer patients at risk of severe infections constitute a small
proportion among patients who regularly receive antibiotic
treatment, not to mention the widespread use of antibiotics
in settings outside the health care system such as agriculture
and livestock. Nonetheless, even such a small population may
have an impact on the general epidemiology of infections, and
reports of spread of resistant pathogens after the introduction
of TMP/SMX or fluoroquinolone prophylaxis have to raise
concern [51, 52]. In particular, multidrug-resistant E. coli and
P. aeruginosa as well as methicillin-resistant S. aureus have
been reported to play a relevant role [51]. However, this
finding has not been confirmed unequivocally [53, 54]. The
2012 Cochrane meta-analysis on antibiotic prophylaxis in
neutropenic cancer patients revealed an increase of infections
due to resistant pathogens in patients receiving antibiotic
prophylaxis with TMP-SMX, but not with fluoroquinolones
[37]. Thus, it is not entirely certain if antibacterial prophylaxis
using fluoroquinolones increases the incidence of infections
with resistant strains. Also, moxifloxacin seems to have the
most relevant potential for inducing C. difficile associated
diarrhea [43], while studies on levofloxacin [55] or ciproflox-
acin [56] prophylaxis did not report a similar increase in the
incidence of C. difficile-associated enterocolitis [39].
In addition, in studies on discontinuation of antibacterial
prophylaxis, an increase in (particularly gram-negative) bac-
teremias has been observed [52, 54, 57], sometimes even
translating into a higher mortality rate [57]. Of note, al-
though some authors report a lack of efficacy in case of a
high incidence of resistance [58], this could not be
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confirmed by others [52, 53, 57]. Thus, a fixed threshold of
for example <20 % prevalence of quinolone resistance for
instituting quinolone prophylaxis as suggested by Bow [59]
cannot be generally advised (E-III). In contrast, it seems more
advisable to monitor development of resistance (A-III) and
efficacy (B-III) on a regular basis in centres implementing
antibiotic prophylaxis. The overall clinical benefit can then be
deduced from local data and experience.
Antibiotic prophylaxis versus myeloid growth factors
for infection prophylaxis
The administration of granulocyte (G-CSF) or granulocyte–
macrophage colony-stimulating factors (GM-CSF) is another
possibility to prevent infectious complications. In studies, a
reduction of bacterial infections could be shown by shortening
the length of neutropenia by the use of these myeloid growth
factors. Therefore, the use is generally recommended if the
risk of febrile neutropenia is above 20 % [60–62]. Two ques-
tions arise, which of these strategies is more efficient, and can
both strategies be combined? A formal meta-analysis compar-
ing both strategies directly could not be performed due to the
different evaluation endpoints of the two small single studies
[63]. Indirect comparisons give the impression, that growth
factors and prophylactic antibiotics show roughly the same
magnitude of efficacy. If antibiotic prophylaxis and growth
factors are combined, it can be assumed from network analy-
ses that efficacy of both strategies add to each other [63], so
that indications for both these approaches to infection preven-
tion should be considered separately.
P. jirovecii prophylaxis
Prophylaxis with trimethoprim–sulfamethoxazole is highly
effective for prevention of Pneumocystis pneumonia (PCP)
and is associated with a decrease in mortality [64]. This could
be demonstrated in studies with HIV patients, but has also been
shown in patients undergoing allogeneic stem cell transplanta-
tion or patients with acute lymphoblastic leukemia (ALL) [65].
Green et al. [66] recommend the use of prophylaxis when the
risk of PCP is greater than 3.5 %. Unfortunately, the studies
included in this meta-analysis are outdated, and data on the
actual risk of PCP in a broad range of hematological malig-
nancies such as acute myeloid leukemia are sparse [65].
Generally, because of more intensive therapy and the use of
newer protocols such as T-cell-depleting substances, an in-
creased incidence can be assumed. In addition, patients with
hematological malignancies appear to have a higher risk of
mortality once they develop a PCP [67]. Thus, prophylaxis is
recommended for patients deemed at significant risk (Table 5).
It should be pointed out that non-neutropenic cancer patients
given glucocorticosteroids for prolonged periods of time, typ-
ically those with brain metastases from solid tumors or cerebral
involvement from non-Hodgkin’s lymphoma, carry a substan-
tial risk of PCP and should be candidates for TMP-SMX
prophylaxis [68]. In some situations, for example, in patients
receiving temozolomide and radiation therapy, the manufac-
turer recommends additional PCP prophylaxis although the
evidence for an increased risk might seem weak. However, in
these situations we recommend to follow the advice given by
the manufacturer.
The drug of first choice for PCP prophylaxis is
TMP/SMX (A-I). The efficacy and tolerability of a daily
and thrice-weekly administration of 960 mg are comparable
[66]. It is recommended to use the drug for the period of
treatment-induced immunosuppression or until CD4 cell
count increases above 200/μl. Due to a potential stem cell
toxicity, it is recommended to begin TMP/SMX after en-
graftment in patients with stem cell transplantation. In case
of intolerance, oral dapsone (100 mg/day), aerosolized pent-
amidine (300 mg every 4 weeks) or oral atovaquone (at least
1,500 mg/day) may be used [66].
Table 5 Recommendations for
Pneumocystis jirovecii
prophylaxis
aIncreased risk: if incidence
greater than 3.5 % (NNT 15)
bIncluding patients without neu-
tropenia, e.g., cerebral metasta-
sis from solid tumor
Infection risk Disease/therapy Level of evidence
Strong evidence for
increased riska
TMP/SMX for the duration of therapy
or until CD4 > 200/μl
A-I
- ALL
- Prolonged CD4 <200/μl
- Long-term steroidsb
Risk status not entirely conclusive TMP/SMX for the duration of therapy C-III
- R-CHOP; BEACOPPesc
- Prolonged neutropenia
- Acute myeloid leukemia
- High dose cytarabine
Consider PCP prophylaxis when recommended by the manufacturer (for example temozolamide and
radiation)
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